ML-180

Research use only, not for human use.

ML-180 is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist (IC50 of 3.7 μM) .ML-180 (0.5-5 μM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells[2]. ML-180 (5 μM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling.

ML-180 is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist (IC50 of 3.7 μM) .ML-180 (0.5-5 μM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells. ML-180 (5 μM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling. ML-180 has a statistically significant decrease of both LRH-1 and SHP mRNA in adrenal glands and pancreatic tissue.

ML-180 (SR1848; 0.01-100 μM; 48 hours) shows diminished capacity to proliferate at concentrations above 1 μM, and the EC50 being roughly 2.8 μM in Huh-7 cells. ML-180 inhibits cell proliferation in an LRH-1-dependent manner. ML-180 (0.5-5 μM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells. ML-180 (5 μM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling. ML-180 (0.5-5 μM; 24 hours) inhibits LRH-1 mRNA expression in a dose-dependent manner. ML-180 (5 μM; 2 hours) rapidly and significantly decreases the mRNA levels of LRH-1 receptor and its downstream targets (CYP19, GATA3, and GATA4) in Huh-7 and HepG2 cells. Cell Proliferation Assay Cell Line:Huh-7 cells Concentration: 0.01, 0.1, 1, 10, 100 μM Incubation Time:48 hours Result:Showed diminished capacity to proliferate at concentrations above 1 μM.Cell Cycle Analysis Cell Line:Huh-7 cells Concentration:0.5, 1, 5 μM Incubation Time:24 hours Result: Showed a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells.Western Blot Analysis Cell Line:Huh-7 cells Concentration:5 μM Incubation Time:24 hours Result:Significantly reduced the LRH-1 protein levels.RT-PCRCell Line:Huh-7 cells Concentration:0.5, 1, 5 μM Incubation Time:24 hours Result:Inhibited LRH-1 mRNA expression in a dose-dependent manner.

ML-180 (SR1848; 30 mg/kg; i.p.; daily; for 10 days) has a statistically significant decrease of both LRH-1 and SHP mRNA in adrenal glands and pancreatic tissue. Animal Model:8-week-old C57Bl/6J mice Dosage:30 mg/kg Administration:IP; daily; for 10 days Result:Had a statistically significant decrease of both LRH-1 and SHP mRNA in adrenal glands and pancreatic tissue.

SR1848

Others

Other Targets

orphan nuclear receptor NR5A2

——

——

863588-32-3

388.89

C20H25ClN4O2

>98% (HPLC)

DMSO:11 mg/mL (28.28 mM; Need ultrasonic)

Clc1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1

——

(-20℃)

With Ice Pack

≥ 2 years